Pharmafile Logo
Pharmafocus logo
Advanced Search

rituximab

Showing 7 posts of 7 posts found.

FDA accepts license application for Novartis’ rituximab biosimilar

September 12, 2017
Manufacturing and Production, Sales and Marketing Novartis, Rituxan, Sandoz, biosimilar, rituximab

Sandoz, Novartis’ generics and biosimilars division, has revealed that the FDA has accepted its Biologics License Application (BLA) for a …

News
shutterstock_212035546

Investigational antibody boosts chemotherapy’s cancer-killing potential

June 29, 2017
Research and Development CFH, Cancer, oncology, rituximab

A proof-of-concept study conducted at the Duke Cancer Institute (DCI) in North Carolina has shown that an investigational antibody has …

News
novartis_side_building

UK launch of two Novartis biosimilars could cut NHS costs

June 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Erelzi, Novartis, Rixathon, Sandoz, biosimilar, etanercept, rituximab

Sandoz, a division of Swiss pharma giant Novartis, has revealed that two of its biosimilars – Rixathon (biosimilar rituximab) and …

News

Sandoz biosimilars as safe and efficacious as originators, says early trials data

June 9, 2016
Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab

Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …

News

Novartis challenges Roche with MabThera biosimilar

January 11, 2011
Research and Development Lonza MabThera, Novartis, Roche, Teva, biosimilar, rituximab

Novartis’ generics unit Sandoz has begun mid-stage trials of a biosimilar version of Roche’s blockbuster drug MabThera. The phase II …

News
Roche's MabThera

NICE recommends MabThera for non-Hodgkin’s lymphoma

December 6, 2010
Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab

NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …

News
ASCObag

ASCO cancer conference opens

June 4, 2010
Research and Development ASCO, Cancer, lenalidomide, rituximab

One of the most important dates in the pharmaceutical industry’s calendar, the ASCO cancer conference begins today. The American Society …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025